

**Evoke Pharma, Inc.**  
**420 Stevens Avenue, Suite 230**  
**Solana Beach, CA 92075**

January 5, 2024

**VIA EDGAR**

Office of Life Sciences  
Division of Corporation Finance  
U.S. Securities and Exchange Commission  
100 F Street N.E.  
Washington, D.C. 20549

**Re: Evoke Pharma, Inc.**  
**Registration Statement on Form S-1, as amended**  
**File No. 333-275443**

Ladies and Gentlemen:

Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Evoke Pharma, Inc. (the “*Company*”), respectfully requests that the effective date of the Registration Statement on Form S-1 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on January 9, 2024, or as soon as practicable thereafter.

Please contact Anthony Gostanian of Latham & Watkins LLP, counsel to the Company, at (858) 523-3969, to provide notice of effectiveness, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter.

Very truly yours,

EVOKE PHARMA, INC.

By: /s/ David A. Gonyer  
David A. Gonyer

Chief Executive Officer

cc: Matthew J. D’Onofrio, *Evoke Pharma, Inc.*  
Matthew T. Bush, *Latham & Watkins LLP*

